Year: 2024
Type: editorial
Abstract: In this issue of Blood, Kogure et al explore the prognostic prediction of circulating tumor DNA (ctDNA) in patients with relapsed/refractory myeloma treated with the same regimen.1 They show that TP53 and KRAS mutations predicted for a poor prognosis, and proposed a scoring system based on the number of detected mutations.[...]
Source: Blood
Author: Jill Corre
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4399391754